Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 20-Apr-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 20-Apr-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.